Evidence map›Paper›PMID 41545068›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

LASER: A Phase 2 Trial of

Shir Hazut Krauthammer, Wanling Xie, Nicole LaBrecque, Luke Arsenault, Liliane Kabarame, Hina Shah, Stephanie Berg, Bradley McGregor, Michael Serzan, Wenxin Xu and 5 more

Abstract readClinical Trial, Phase II
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shir Hazut KrauthammerDepartment of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts; skrauthammer@mgb.org.
Wanling XieDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts; and.
Nicole LaBrecqueDepartment of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts.
Luke ArsenaultLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Liliane KabarameLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hina ShahDepartment of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts.
Stephanie BergLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Bradley McGregorLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Michael SerzanLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Wenxin XuLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Srinivas R ViswanathanLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Xiao X WeiLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Toni K ChoueiriLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Heather JaceneDepartment of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts.
Praful RaviLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6M
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4M
Lymph Node Quantification System for Multisite Clinical TrialsR01CA235589 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GORDON J HARRIS, Ron Kikinis · 2019 to 2026
$4.5M
Probing the role of somatic X-chromosome alterations in shaping cancer sex differencesR01CA286652 · NCI · DANA-FARBER CANCER INST · PI VISWANATHAN, SRINIVAS RAGHAVAN, ZHANG, CHENG-ZHONG · 2023 to 2025
$2.7M
Role of ctDNA change as a response measure in the EA1183 patient population and how ctDNA changes correlate with metabolic response by serial FDG PET/CTR01CA251803 · NCI · UNIVERSITY OF WASHINGTON · PI SPECHT, JENNIFER MARIE · 2021 to 2025
$1.5M
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylationU01CA269505 · NCI · DANA-FARBER CANCER INST · PI Srinivas Raghavan Viswanathan · 2025 to 2026
$1.0M
NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA235589NCI NIH HHS R01 CA251803NCI NIH HHS R01 CA286652NCI NIH HHS U01 CA269505
6 · The paper itself

Abstract

Renal cell carcinoma is one of the most common malignancies in the United States, with clear cell renal cell carcinoma (ccRCC) comprising approximately 70% of all cases. ccRCC remains therapeutically challenging, particularly in patients whose disease progresses after therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors. Prostate-specific membrane antigen (PSMA), expressed in the tumor neovasculature of ccRCC, offers a potential therapeutic target for radiopharmaceutical therapy with

Indexed as

Carcinoma, Renal CellDipeptidesHeterocyclic Compounds, 1-RingKidney NeoplasmsLutetiumProstate-Specific AntigenHumansMaleRadioisotopesRadiopharmaceuticalsTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617RadioisotopesRadiopharmaceuticals177Lu-PSMA-617clear cell renal cell carcinomaclinical trial protocolPSMAradiopharmaceutical therapy

Identifiers

PMID41545068
PMCPMC13670995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.